Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tolazamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.75 |
| ▸ | LMNA | P02545 | 4/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.75 |
| ▸ | TSHR | P16473 | 2/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.75 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.75 |
| ▸ | ALB | P02768 | 1/20 | 0.75 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.75 |
| ▸ | TP53 | P04637 | 1/20 | 0.75 |
| ▸ | GLA | P06280 | 1/20 | 0.75 |
| ▸ | GAA | P10253 | 1/20 | 0.75 |
| ▸ | MAPT | P10636 | 1/20 | 0.75 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.75 |
| ▸ | FBP1 | P09467 | 3/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tolazamide SCHEMBL747962 | 0.93 | ALDH1A1 (0.65) | ALDH1A1LMNACYP2C9TSHRCYP3A4 | |
| Tolazamide SCHEMBL2534564 | 0.88 | ALDH1A1 (0.70) | ALDH1A1LMNACYP2C9TSHRCYP3A4 | |
| Tolazamide SCHEMBL13725632 | 0.87 | ALDH1A1 (1.00) | ALDH1A1LMNACYP2C9TSHRCYP3A4 | |
| Tolbutamide SCHEMBL15918 | 0.87 | ALDH1A1 (1.00) | ALDH1A1LMNACYP2C9TSHRCYP3A4 | |
| Tolazamide SCHEMBL34417 | 0.87 | ALDH1A1 (1.00) | ALDH1A1LMNACYP2C9TSHRCYP3A4 | |
| Tolbutamide SCHEMBL1536920 | 0.87 | ALDH1A1 (1.00) | ALDH1A1LMNACYP2C9TSHRCYP3A4 | |
| Glypinamide SCHEMBL5243890 | 0.86 | ALDH1A1 (0.59) | ALDH1A1LMNACYP2C9TSHRCYP3A4 | |
| Tolbutamide SCHEMBL140363 | 0.85 | ALDH1A1 (0.97) | ALDH1A1LMNACYP2C9TSHRCYP3A4 | |
| Tolbutamide SCHEMBL11357518 | 0.85 | ALDH1A1 (0.97) | ALDH1A1LMNACYP2C9TSHRCYP3A4 | |
| Tolbutamide SCHEMBL11356450 | 0.85 | ALDH1A1 (0.97) | ALDH1A1LMNACYP2C9TSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458033-B1 | TRIPLE DRUG COMBINATION (METFORMIN, SIMVASTATIN, DIGOXIN) FOR TARGETED TREATMENT OF PANCREATIC CANCER | UNIV CALIFORNIA (US) | 2023-07-05 | — | — | EP | disclosed |
| US-11197844-B2 | Triple drug combination (metformin, simvastatin, digoxin) for targeted treatment of pancreatic cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-12-14 | — | — | US | disclosed |
| US-20210100770-A1 | TRIPLE DRUG COMBINATION (METFORMIN, SIMVASTATIN, DIGOXIN) FOR TARGETED TREATMENT OF PANCREATIC CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-04-08 | — | — | US | disclosed |
| US-10813909-B2 | Triple drug combination (metformin, simvastatin, digoxin) for targeted treatment of pancreatic cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-10-27 | — | — | US | disclosed |
| EP-3458033-A2 | TRIPLE DRUG COMBINATION (METFORMIN, SIMVASTATIN, DIGOXIN) FOR TARGETED TREATMENT OF PANCREATIC CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-03-27 | — | — | EP | disclosed |
| WO-2018044369-A2 | TRIPLE DRUG COMBINATION (METFORMIN, SIMVASTATIN, DIGOXIN) FOR TARGETED TREATMENT OF PANCREATIC CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-03-08 | — | — | WO | disclosed |
| EP-1014941-B2 | HOT-MELT EXTRUDABLE PHARMACEUTICAL FORMULATION | UNIV TEXAS (US) | 2017-05-17 | — | — | EP | disclosed |
| US-9198865-B2 | Biologically active composition comprising ethylcellulose | DOW GLOBAL TECHNOLOGIES LLC | 2015-12-01 | — | — | US | disclosed |
| EP-2272536-A2 | Hot-melt extrudable Pharmaceutical formulation | Board of Regents, The University of Texas System (US) | 2011-01-12 | — | — | EP | disclosed |
| EP-1978940-B1 | BIOLOGICALLY ACTIVE COMPOSITION COMPRISING ETHYLCELLULOSE | DOW GLOBAL TECHNOLOGIES INC (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-1978940-A2 | BIOLOGICALLY ACTIVE COMPOSITION COMPRISING ETHYLCELLULOSE | DOW GLOBAL TECHNOLOGIES INC. (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007084212-A2 | BIOLOGICALLY ACTIVE COMPOSITION COMPRISING ETHYLCELLULOSE | DOW GLOBAL TECHNOLOGIES INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| US-20060251724-A1 | Method for preparing thermoformed compositions containing acrylic polymer binders, pharmaceutical dosage forms and methods of preparing the same | BPSI HOLDINGS, INC. | 2006-11-09 | — | — | US | disclosed |
| EP-1624859-A2 | METHOD FOR PREPARING THERMOFORMED COMPOSITIONS CONTAINING ACRYLIC POLYMER BINDERS, PHARMACEUTUAL DOSAGE FORMS AND METHODS OF PREPARING THE SAME | BPSI Holdings, Inc. (US) | 2006-02-15 | — | — | EP | disclosed |
| EP-1014941-A4 | HOT-MELT EXTRUDABLE PHARMACEUTICAL FORMULATION | UNIV TEXAS (US) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004100883-A2 | METHOD FOR PREPARING THERMOFORMED COMPOSITIONS CONTAINING ACRYLIC POLYMER BINDERS, PHARMACEUTUAL DOSAGE FORMS AND METHODS OF PREPARING THE SAME | BPSI HOLDINGS, INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| US-6488963-B1 | POLYETHYLENE OXIDE FORMULATIONS THAT ARE NOT FILM-LIKE PREPARATIONS; CONTROLLED DRUG DELIVERY | THE UNIVERSITY OF TEXAS SYSTEM | 2002-12-03 | — | — | US | disclosed |
| EP-1014941-A1 | HOT-MELT EXTRUDABLE PHARMACEUTICAL FORMULATION | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-1997049384-A1 | HOT-MELT EXTRUDABLE PHARMACEUTICAL FORMULATION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1997-12-31 | — | — | WO | disclosed |
| US-5143731-A | Administering hyperosmotic, isoosmotic, or hypoosmotic thermo-irreversible gel as drug vehicle | MEDIVENTURES INCORPORATED (US) | 1992-09-01 | — | — | US | disclosed |